Worth reading
—
Scored from 0 of 3 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
448
¥100 million (estimated equity value)Wording
Avoiding a definitive answer
How definitive the wording is.What was corrected and how
A subsequent correction by the company to the contents of an already published filing.
Original disclosure
The number of days elapsed cannot be calculated because the original disclosure date is unknown.
This correction2026-06-05
| Item | Details |
|---|
Items this document does not state (6)
Disclosure subject to correctionOriginal disclosure dateLocation of correctionDetails of correctionReason for correctionImpact on Business Performance
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To integrate あゆみ製薬's domestic business platform, strengthen GNI's domestic operating and personnel base, and introduce and expand GNI's development products and overseas pharmaceuticals and biosimilars in the Japanese market. The company also cites strengthening its earnings base, expanding its pipeline, and creating synergies to enhance long-term shareholder value as strategic significance.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.